ABSCI CORP Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
ABSCI CORP (ABSI) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $155.72 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2023-03-30
- ABSCI CORP adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2021-09-30 was $155.72M.
- ABSCI CORP adjustments to additional paid in capital, equity component of convertible debt for fiscal 2021 was $155.72M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|
| 2021-12-31 | $155.72M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $155.72M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |